NCT03901339: Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

NCT03901339
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least 2, & no more than 4, prior chemotherapy regimens, at least 1 prior anticancer hormonal treatment, & at least 1 CDK 4/6 inhibitor for metastatic disease
Exclusions: Patients with previous treatment with Topoisomerase 1 Inhibitors
https://ClinicalTrials.gov/show/NCT03901339

Comments are closed.

Up ↑